Neurofibromatosis
2
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 2 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
AstraZenecaCAMBRIDGE, United Kingdom
1 programClinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsiaN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
PfizerSutent®/Sunitinib
SandozTasigna
AstraZenecaClinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsia
Clinical Trials (3)
Total enrollment: 225 patients across 3 trials
Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas
Start: Mar 2012Est. completion: Feb 201819 patients
Phase 2Terminated
Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Start: Jan 2011Est. completion: Oct 20166 patients
Phase 1Completed
NCT07088991AstraZenecaClinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsia
Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsia
Start: Jun 2025Est. completion: Mar 2028200 patients
N/ARecruiting
Related Jobs
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 225 patients
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.